While the use of human cells would be ideal, this is a significant challenge as immune cells would have to originate from the same organism as the cancer cells in the assay to avoid indiscriminate killing by immune rejection, i.e., antigens derived from cells of another organism being recognized by CD8+ T cells as foreign. This evidence concerns the gene CD8A and cancer.